These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35024237)

  • 1. Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib.
    Nogueira M; Torres T
    Dermatol Pract Concept; 2021 Oct; 11(4):e2021145. PubMed ID: 35024237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus kinase inhibitors for the therapy of atopic dermatitis.
    Traidl S; Freimooser S; Werfel T
    Allergol Select; 2021; 5():293-304. PubMed ID: 34532638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
    Wood H; Chandler A; Nezamololama N; Papp K; Gooderham MJ
    Int J Dermatol; 2022 Jun; 61(6):746-754. PubMed ID: 34423443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    Sun C; Su Z; Zeng YP
    Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibitors in the treatment of atopic dermatitis.
    Chovatiya R; Paller AS
    J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Janus kinase inhibitors in atopic dermatitis - an update.
    Dhar S; Datta S; De A
    Indian J Dermatol Venereol Leprol; 2023 Oct; ():1-8. PubMed ID: 38031681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Janus kinase inhibitors for atopic dermatitis.
    Mikhaylov D; Ungar B; Renert-Yuval Y; Guttman-Yassky E
    Ann Allergy Asthma Immunol; 2023 May; 130(5):577-592. PubMed ID: 36736457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The suitability of treating atopic dermatitis with Janus kinase inhibitors.
    Narla S; Silverberg JI
    Expert Rev Clin Immunol; 2022 May; 18(5):439-459. PubMed ID: 35377276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Narla S; Silverberg JI
    Dermatitis; 2024; 35(S1):S24-S38. PubMed ID: 37527229
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis.
    Lee KP; Plante J; Korte JE; Elston DM
    Skin Health Dis; 2023 Feb; 3(1):e133. PubMed ID: 36751339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis.
    Pereyra-Rodriguez JJ; Alcantara-Luna S; Domínguez-Cruz J; Galán-Gutiérrez M; Ruiz-Villaverde R; Vilar-Palomo S; Armario-Hita JC
    Life (Basel); 2021 Sep; 11(9):. PubMed ID: 34575076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
    Gao Q; Zhao Y; Zhang J
    Heliyon; 2023 Jun; 9(6):e16704. PubMed ID: 37332971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.